3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Conditions
Pain
2
Neoplasms
2
Interventions
Gemcitabine
109
Paclitaxel
92
Carboplatin
79
pembrolizumab
75
Bevacizumab
75
Surveys and Questionnaires
70
Docetaxel
69
Cisplatin
67
Nivolumab
48
Exercise
48
Capecitabine
48
Cyclophosphamide
47
Sorafenib
43
Fluorouracil
43
Irinotecan
42
Pemetrexed
37
Albumin-Bound Paclitaxel
35
Radiotherapy
34
Dexamethasone
34
Blood Specimen Collection
34
Oxaliplatin
31
Leucovorin
31
Erlotinib Hydrochloride
31
trametinib
30
130-nm albumin-bound paclitaxel
29
Cetuximab
28
Therapeutics
26
Ipilimumab
26
Standard of Care
25
Methods
25
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Completed
×
Neoplasms
×
Tetrodotoxin
×
Clear all
NCT00725114
2014-07-09
TEC-006
Wex Pharmaceuticals Inc.
Phase 3
Completed
165 enrolled
NCT00726011
2012-10-24
TEC-006OL
Wex Pharmaceuticals Inc.
Phase 3
Completed
113 enrolled